Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab Extension in Thyroid Eye Disease
NCT03461211Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2018
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of teprotumumab in thyroid eye disease (TED), sponsored by Amgen. Primary endpoint: Percentage of Participants With a >= 2 mm Reduction From Baseline in the Study Eye Without Deterioration of Proptosis in the Fellow Eye at 24 weeks. Started Apr 2018; status: completed.
02
Drugs
teprotumumab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT03461211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03461211.